- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Nephros provided an update to shareholders of their “activities and guidance” during the third quarter of 2017.
Nephros (OTCQB:NEPH) provided an update to shareholders of their “activities and guidance” during the third quarter of 2017.
As quoted in the press release:
General Corporate Update
HydraGuardand EndoPurUltrafilters
The Company has begun selling all versions of the EndoPur and HydraGuard to dialysis clinics and hospital facilities, respectively.
Commercial and Industrial Filtration Products
The Company expects to launch its 9,000 gallon lead-removal filter before the end of 2017. The dual stage filter will absorb soluble lead and retain particulate lead to provide a comprehensive solution for water that exceeds a lead concentration of 150 parts per million.
OLpūr H2H Hemodiafiltration Module
Vanderbilt University continues to treat patients with the Nephros OLpūr® H2H Hemodiafiltration Module. The Company has made additional progress in the development of the second generation hemodiafiltration module and expects to increase these activities as the Company achieves positive cash flow.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.